JERUSALEM--(BUSINESS WIRE)--Intec Pharma Ltd. (Nasdaq:NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the Rodman & Renshaw 18th Annual Global Investment Conference taking place from September 11-13, 2016 in New York City and Maxim Group LLC & Edison’s Inaugural Israel Day taking place on September 14, 2016 in New York City.
Rodman & Renshaw 18th Annual Global Investment Conference
Date
and Time: September 12, 2016, 3:25 PM EDT
Website: Rodman
& Renshaw 18th Annual Global Investment Conference
Format: Company
presentation
Presenter: Zeev Weiss, Chief Executive Officer
Maxim Group LLC & Edison’s Inaugural Israel Day
Date: September
14, 2016, 10:30 AM EDT
Format: Company presentation
Presenter: Zeev
Weiss, Chief Executive Officer
Mr. Weiss’ presentation from the September conferences will be available on the Company’s website at www.intecpharma.com.
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, currently in Phase III, Accordion Pill Zaleplon, or AP-ZP, which is being developed for the treatment of insomnia, including sleep induction and sleep maintenance, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel ulcers induced by Nonsteroidal Anti-Inflammatory Drugs. In addition, an Accordion Pill for cannabinoid therapies (AP-CBD/THC) will enter Phase I clinical trial in the first quarter of 2017.